Ascletis Announces Submission of Marketing Authorization Application for Ritonavir in Hong Kong
- Sunday, April 3, 2022, 7:04
- Finance
- Add a comment
HANGZHOU and SHAOXING, China, April 3, 2022 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672) today announces that it has submitted the marketing authorization application for ritonavir (100 mg film-coated tablet) in the Hong Kong Special Administrative Region of the People’s Republic of…
About the Author
adminasapcorp has written 39120 stories on this site.